Bradley Layton
Family Medicine · Oneida, NYNPI 1740202597
Payments from drug & device makers
Across 193 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$619
- Novo Nordisk$487
- Lilly USA, LLC$322
- Amarin Pharma, Inc.$268
- AstraZeneca$211
- AbbVie$140
- plus $993 from 24 others
What the payments were for
- Food & beverage$3,034100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 37 | $619 |
| Novo Nordisk | 33 | $487 |
| Lilly USA, LLC | 21 | $322 |
| Amarin Pharma, Inc. | 20 | $268 |
| AstraZeneca | 13 | $211 |
| AbbVie(2 entities) | 9 | $140 |
| Teva Pharmaceuticals USA, Inc. | 6 | $98 |
| Johnson & Johnson | 5 | $97 |
| Abbott | 4 | $76 |
| Alkermes, Inc. | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| Merck | 5 | $65 |
| Boehringer Ingelheim | 4 | $58 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $45 |
| Exact Sciences | 3 | $44 |
| Shield Therapeutics Inc | 2 | $35 |
| Amgen(2 entities) | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $25 |
| Insulet Corporation | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Pfizer | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$3,040 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $90,453 |
| RybelsusSemaglutide | 53 | $49,043 |
| JardianceEmpagliflozin | 39 | $31,771 |
| EliquisApixaban | 42 | $26,559 |
| JanuviaSitagliptin Phosphate | 37 | $22,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $20,741 |
| OzempicSemaglutide | 14 | $12,942 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,597 |
| VascepaIcosapent Ethyl | 26 | $6,038 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,396 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $3,034 |
| Novolog FlexpenInsulin Aspart | 13 | $2,974 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,959 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,899 |
| Levothyroxine Sodium | 108 | $2,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $487 | $61,98467 claims |
| Boehringer IngelheimJardiance | $58 | $31,77139 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $619 | $29,03659 claims |
| PfizerEliquis | $16 | $26,55942 claims |
| MerckJanuvia | $65 | $22,31337 claims |
| AbbVieSynthroid | $140 | $1,76031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Oneida
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.